AYTU vs AZN

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite unprofitability (ROE: -50.23%, Profit Margin: -20.52%) and declining revenue (YoY -16.20%), the stock has seen strong short-term price momentum (+61.7% 1Y) and a bullish analyst recommendation (strong_buy) with a high target price of $9.33. High gross margins (67.56%) and improving quarterly earnings surprises (avg +98.68% last 4 quarters) suggest operational progress, but weak cash visibility, leverage (Debt/Equity: 1.23), and inconsistent earnings history remain concerns. The stock trades at a forward P/E of 15.88, below sector average, potentially reflecting skepticism around sustainability.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.